Abstract
Background
For patients with ST elevation myocardial infarction (STEMI) or non‐ST elevation myocardial infarction (NSTEMI), rapid restoration of coronary blood flow is the primary therapeutic goal. Because of the acute nature of this clinical presentation, bleeding risks may not be adequately evaluated, limiting the use of drug‐eluting stents, since premature discontinuation of antiplatelet therapy strongly predicts stent thrombosis. We evaluated angiographic and clinical results of non‐drug‐eluting carbon‐coated stents.
Methods
In this prospective observational study, angiographic and clinical 6‐mo results of a carbon‐coated stent for treatment of acute lesions in native coronary arteries were evaluated. Angiographic main outcome measures included in‐stent late loss and binary restenosis rate. Major adverse cardiac events (MACEs) were defined as any death, Q‐wave myocardial infarction (MI), and target lesion revascularization.
Results
We included 320 patients with STEMI (n = 205) or NSTEMI (n = 115) with 360 lesions. Reference vessel diameter was 2.93 ± 0.53 mm and stented length 22.7 ± 13.8 mm. Angiographic follow‐up was available in 220 of 360 lesions (61%). In‐stent late loss was 0.69 ± 0.75 mm, with a binary restenosis rate of 19.1%. For the total segment late loss was 0.74 ± 0.77 mm and binary restenosis rate 21.4%. Clinical follow‐up for 97.4% of discharged patients was available. Hierarchical MACEs were death in 14 patients (4.4%), Q‐wave MI in 3 patients (0.9%), and target lesion revascularization in 39 patients (12.2%).
Conclusion
In this prospective, observational study, the use of a carbon‐coated stent for treatment of lesions in patients with STEMI or NSTEMI was associated with a low late loss, translating into a low binary angiographic restenosis rate within a 6‐mo follow‐up. Copyright © 2008 Wiley Periodicals, Inc.
Keywords: acute coronary syndromes, myocardial infarction, clinical trials, catheterization, angiography
Full Text
The Full Text of this article is available as a PDF (107.4 KB).
References
- 1. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, et al.: Paclitaxel‐eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355: 1105–1113. [DOI] [PubMed] [Google Scholar]
- 2. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, et al.: Sirolimus‐eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093–1104. [DOI] [PubMed] [Google Scholar]
- 3. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, et al.: Long‐term outcomes with drug‐eluting stents versus bare‐metal stents in Sweden. N Engl J Med 2007; 356: 1009–1019. [DOI] [PubMed] [Google Scholar]
- 4. Nordmann AJ, Briel M, Bucher HC: Mortality in randomized controlled trials comparing drug‐eluting vs. bare metal stents in coronary artery disease: a meta‐analysis. Eur Heart J 2006; 27: 2784–2814. [DOI] [PubMed] [Google Scholar]
- 5. Park DW, Park SW, Park KH, Lee BK, Kim YH, et al.: Frequency of and risk factors for stent thrombosis after drug‐eluting stent implantation during long‐term follow‐up. Am J Cardiol 2006; 98: 352–356. [DOI] [PubMed] [Google Scholar]
- 6. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug‐eluting stents. JAMA 2005; 293: 2126–2130. [DOI] [PubMed] [Google Scholar]
- 7. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, et al.: Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug‐eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803–2809. [DOI] [PubMed] [Google Scholar]
- 8. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, et al.: Bare metal stent restenosis is not a benign clinical entity. Am Heart J 2006; 151: 1260–1264. [DOI] [PubMed] [Google Scholar]
- 9. Schuhlen H, Kastrati A, Mehilli J, Hausleiter J, Pache J, et al.: Restenosis detected by routine angiographic follow‐up and late mortality after coronary stent placement. Am Heart J 2004; 147: 317–322. [DOI] [PubMed] [Google Scholar]
- 10. Morice MC, Bestehorn HP, Carrié D, Macaya C, Verheye S, et al.: Direct stenting of de novo coronary stenoses with tacrolimus‐eluting versus carbon‐coated carbostents. The randomized JUPITER II trial. Euro Interv 2006; 2: 45–52. [PubMed] [Google Scholar]
- 11. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, et al.: A polymer‐based, paclitaxel‐eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221–231. [DOI] [PubMed] [Google Scholar]
- 12. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, et al.: Sirolimus‐eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315–1323. [DOI] [PubMed] [Google Scholar]
- 13. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, et al.: Randomized, double‐blind, multicenter study of the Endeavor zotarolimus‐eluting phosphorylcholine‐encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798–806. [DOI] [PubMed] [Google Scholar]
- 14. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, et al.: A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1879–1885. [DOI] [PubMed] [Google Scholar]
- 15. Weber F, Schneider H, Schwarz C, Holzhausen C, Petzsch M, et al.: Sirolimus‐eluting stents for percutaneous coronary intervention in acute myocardial infarction Lesson from a case‐controlled comparison of bare metal versus drug‐eluting stents in thrombus‐laden lesions. Z Kardiol 2004; 93: 938–943. [DOI] [PubMed] [Google Scholar]
- 16. Stone GW, Brodie BR, Griffin JJ, Costantini C, Morice MC, et al.: Clinical and angiographic follow‐up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction (PAMI) stent pilot trial. Circulation 1999; 99: 1548–1554. [DOI] [PubMed] [Google Scholar]
- 17. Sick PB, Gelbrich G, Kalnins U, Erglis A, Bonan R, et al.: Comparison of early and late results of a Carbofilm‐coated stent versus a pure high‐grade stainless steel stent (the Carbostent‐Trial). Am J Cardiol 2004; 93: 1351–1356. [DOI] [PubMed] [Google Scholar]
- 18. Danzi GB, Capuano C, Sesana M, Baglini R, Bartorelli AL, et al.: Six‐mo clinical and angiographic outcomes of the Tecnic Carbostent coronary system: the phantom IV study. J Invasive Cardiol 2004; 16: 641–644. [PubMed] [Google Scholar]
- 19. Pache J, Kastrati A, Mehilli J, Schuhlen H, Dotzer F, et al.: Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR‐STEREO‐2) trial. J Am Coll Cardiol 2003; 41: 1283–1288. [DOI] [PubMed] [Google Scholar]
- 20. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, et al.: Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR‐STEREO) trial. Circulation 2001; 10: 2816–2821. [DOI] [PubMed] [Google Scholar]
- 21. Van de Werf F: Drug‐eluting stents in acute myocardial infarction. N Engl J Med 2006; 355: 1169–1170. [DOI] [PubMed] [Google Scholar]